---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-23-000077"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:12:33.716165+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Instil Bio preclinical data show FRα-CoStAR enhances TIL activity; clinical restart H2 2023

## Summary
- Oral presentation at BSGCT conference on ITIL-306 preclinical data.
- FRα-CoStAR enhanced TIL activity against autologous NSCLC, ovarian, and renal tumors.
- Enhanced activity exceeded melanoma TILs as measured by IFNγ secretion.
- ITIL-306 clinical study anticipated to resume in 2H 2023; initial clinical data expected in 2024.

## SEC filing metadata
- accession: 0001789769-23-000077
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000077/0001789769-23-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000077/til-20230626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-23-000077
- JSON: https://secwatch.observer/filing/0001789769-23-000077.json
- Plain text: https://secwatch.observer/filing/0001789769-23-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.